Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment

被引：0
|
作者：
Genovese, Mark C. [1 ]
van Hoogstraten, Hubert [2 ]
St John, Gregory [3 ]
Dong, Qunming [2 ]
Jose Gomez-Reino, Juan [4 ]
Maldonado-Cocco, Jose A. [5 ]
Carlos Salazar, Juan [6 ]
Huizinga, Tom W. J. [7 ]
Burmester, Gerd R. [8 ]
机构：
[1] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[2] Sanofi Genzyme, Bridgewater, NJ USA
[3] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[4] Complejo Hosp Univ Santiago de Compostela, Santiago, Spain
[5] Buenos Aires Univ, Sch Med, Buenos Aires, DF, Argentina
[6] Riesgo Fractura SA CAYRE, Bogota, Colombia
[7] Leiden Univ, Med Ctr, Leiden, Netherlands
[8] Charite Univ Med Berlin, Berlin, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2509
引用
收藏
页数：3
相关论文
共 50 条
  • [1] LONG-TERM TREATMENT WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): POOLED SAFETY AND EFFICACY WITH OVER 4 YEARS' TREATMENT
    van Hoogstraten, Hubert
    St John, Gregory
    Thangavelu, Karthinathan
    Jose Gomez-Reino, Juan
    Antonio Maldonado-Cocco, Jose
    Carlos Salazar, Juan
    Huizinga, Thomas
    Wilson, Elaine
    Burmester, Gerd R.
    [J]. RHEUMATOLOGY, 2019, 58 : 74 - 75
  • [2] Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    Van Vollenhoven, R. F.
    Rowe, K.
    Agarwa, S.
    Shaw, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 58 - 58
  • [3] Long-term efficacy and safety of a repeat treatment course of rituximab in RA patients with an inadequate response to disease-modifying anti-rheumatic drugs.
    Emery, P.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    van Vollenhoven, R. F.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S228 - S228
  • [4] Long-term efficacy and safety of a repeat treatment course of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs
    Emery, P.
    van Vollenhoven, R. F.
    Furst, D. E.
    Ferraccioli, G.
    Udell, J.
    Rowe, K.
    Agarwal, S.
    Shaw, T.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 40 - 41
  • [5] Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data
    Morgan, Christopher Ll
    Emery, Paul
    Porter, Duncan
    Reynolds, Alan
    Young, Adam
    Boyd, Helen
    Poole, Chris D.
    Currie, Craig J.
    [J]. RHEUMATOLOGY, 2014, 53 (01) : 186 - 194
  • [6] Safety of long-term use of four common conventional disease modifying anti-rheumatic drugs in rheumatoid arthritis
    Kedia, Arun Kumar
    Mohansundaram, Kavitha
    Goyal, Mohit
    Ravindran, Vinod
    [J]. JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2021, 51 (03): : 237 - 245
  • [7] Efficacy and safety of infliximab: A comparison with other biological disease-modifying anti-rheumatic drugs
    Kobayashi, Daisuke
    Ito, Satoshi
    Takai, Chinatsu
    Hasegawa, Eriko
    Nomura, Yumi
    Otani, Hiroshi
    Abe, Asami
    Ishikawa, Hajime
    Murasawa, Akira
    Narita, Ichiei
    Nakazono, Kiyoshi
    [J]. MODERN RHEUMATOLOGY, 2018, 28 (04) : 599 - 605
  • [8] EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Zeng, X.
    Liu, Y.
    Hu, J.
    Li, J.
    Wang, Y.
    Zhao, D.
    Wu, L.
    Xiao, Z.
    Li, Z.
    Xu, J.
    Meerwein, S.
    Xie, Y.
    Liang, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1324 - 1324
  • [9] INCONSISTENT TREATMENT WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS: A LONGITUDINAL DATA ANALYSIS
    Mjaavatten, M. D.
    Radner, H.
    Yoshida, K.
    Shadick, N. A.
    Frits, M. L.
    Iannaccone, C. K.
    Kvien, T. K.
    Weinblatt, M. E.
    Solomon, D. H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 167 - 167
  • [10] Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up
    Fleischmann, Roy
    Lin, Yong
    St John, Gregory
    van der Heijcle, Desiree
    Qiu, Chunfu
    Jose Gomez-Reino, Juan
    Maldonado-Cocco, Jose A.
    Stanislav, Marina
    Seriolo, Bruno
    Burmester, Gerd R.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345